Current Screening Methodologies in Drug Discovery for Selected Human Diseases

Overview

Journal Mar Drugs

Publisher MDPI

Specialties Biology
Pharmacology

Date 2018 Aug 17

PMID 30110923

Citations 41

Authors

Olga Maria Lage

Maria C Ramos

Rita Calisto

Eduarda Almeida

Vitor Vasconcelos

Francisca Vicente

Affiliations

Soon will be listed here.

Abstract

The increase of many deadly diseases like infections by multidrug-resistant bacteria implies re-inventing the wheel on drug discovery. A better comprehension of the metabolisms and regulation of diseases, the increase in knowledge based on the study of disease-born microorganisms' genomes, the development of more representative disease models and improvement of techniques, technologies, and computation applied to biology are advances that will foster drug discovery in upcoming years. In this paper, several aspects of current methodologies for drug discovery of antibacterial and antifungals, anti-tropical diseases, antibiofilm and antiquorum sensing, anticancer and neuroprotectors are considered. For drug discovery, two different complementary approaches can be applied: classical pharmacology, also known as phenotypic drug discovery, which is the historical basis of drug discovery, and reverse pharmacology, also designated target-based drug discovery. Screening methods based on phenotypic drug discovery have been used to discover new natural products mainly from terrestrial origin. Examples of the discovery of marine natural products are provided. A section on future trends provides a comprehensive overview on recent advances that will foster the pharmaceutical industry.

Citing Articles

3D bioprinting for the construction of drug testing models-development strategies and regulatory concerns.

Mallya D, Gadre M, Varadharajan S, Vasanthan K Front Bioeng Biotechnol. 2025; 13:1457872.

PMID: 40028291 PMC: 11868281. DOI: 10.3389/fbioe.2025.1457872.

Targeting SARS-CoV-2 main protease: a comprehensive approach using advanced virtual screening, molecular dynamics, and in vitro validation.

Gevorgyan S, Khachatryan H, Shavina A, Gharaghani S, Zakaryan H Virol J. 2024; 21(1):330.

PMID: 39707350 PMC: 11662536. DOI: 10.1186/s12985-024-02607-4.

Genome-wide pan-GPCR cell libraries accelerate drug discovery.

Yang H, Wang Y, Liu W, He T, Liao J, Qian Z Acta Pharm Sin B. 2024; 14(10):4296-4311.

PMID: 39525595 PMC: 11544303. DOI: 10.1016/j.apsb.2024.06.023.

Development of a new experimental NMR strategy for covalent cysteine protease inhibitors screening: toward enhanced drug discovery.

Chihab A, El Brahmi N, Hamdoun G, El Abbouchi A, Ghammaz H, Touil N RSC Adv. 2024; 14(37):26829-26836.

PMID: 39184001 PMC: 11342919. DOI: 10.1039/d4ra04938a.

Comparative Cross-Kingdom DDA- and DIA-PASEF Proteomic Profiling Reveals Novel Determinants of Fungal Virulence and a Putative Druggable Target.

Ball B, Sukumaran A, Krieger J, Geddes-McAlister J J Proteome Res. 2024; 23(9):3917-3932.

PMID: 39140824 PMC: 11385706. DOI: 10.1021/acs.jproteome.4c00255.

References

Spangenberg T, Burrows J, Kowalczyk P, McDonald S, Wells T, Willis P . The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS One. 2013; 8(6):e62906. PMC: 3684613. DOI: 10.1371/journal.pone.0062906. View

Chauhan J, Luthra T, Gundla R, Ferraro A, Holzgrabe U, Sen S . A diversity oriented synthesis of natural product inspired molecular libraries. Org Biomol Chem. 2017; 15(43):9108-9120. DOI: 10.1039/c7ob02230a. View

Vasaikar S, Bhatia P, Bhatia P, Yaiw K . Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets. Biomedicines. 2017; 4(4). PMC: 5344266. DOI: 10.3390/biomedicines4040027. View

Choma I, Grzelak E . Bioautography detection in thin-layer chromatography. J Chromatogr A. 2011; 1218(19):2684-91. DOI: 10.1016/j.chroma.2010.12.069. View

Hu Y, Chen J, Hu G, Yu J, Zhu X, Lin Y . Statistical research on the bioactivity of new marine natural products discovered during the 28 years from 1985 to 2012. Mar Drugs. 2015; 13(1):202-21. PMC: 4306932. DOI: 10.3390/md13010202. View

Perez R, Godwin A, Handel L, Hamilton T . A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur J Cancer. 1993; 29A(3):395-9. DOI: 10.1016/0959-8049(93)90394-u. View

Romar G, Kupper T, Divito S . Research Techniques Made Simple: Techniques to Assess Cell Proliferation. J Invest Dermatol. 2016; 136(1):e1-e7. DOI: 10.1016/j.jid.2015.11.020. View

Langjae R, Bussarawit S, Yuenyongsawad S, Ingkaninan K, Plubrukarn A . Acetylcholinesterase-inhibiting steroidal alkaloid from the sponge Corticium sp. Steroids. 2007; 72(9-10):682-5. DOI: 10.1016/j.steroids.2007.05.005. View

Paveley R, Bickle Q . Automated imaging and other developments in whole-organism anthelmintic screening. Parasite Immunol. 2013; 35(9-10):302-13. DOI: 10.1111/pim.12037. View

10.

Goodwin C, Holt S, Downes S, Marshall N . Microculture tetrazolium assays: a comparison between two new tetrazolium salts, XTT and MTS. J Immunol Methods. 1995; 179(1):95-103. DOI: 10.1016/0022-1759(94)00277-4. View

11.

Wang H, Li R, Shen Y . β-Secretase: its biology as a therapeutic target in diseases. Trends Pharmacol Sci. 2013; 34(4):215-25. PMC: 3691103. DOI: 10.1016/j.tips.2013.01.008. View

12.

Chakrabarti E, Smith J . Drug library screen to identify compounds that decrease secreted Abeta from a human cell line. Curr Alzheimer Res. 2005; 2(2):255-9. DOI: 10.2174/1567205053585738. View

13.

Yang Z, Fang Z, He W, Wang Z, Gan H, Tian Q . Identification of inhibitors for vascular endothelial growth factor receptor by using dynamic combinatorial chemistry. Bioorg Med Chem Lett. 2016; 26(7):1671-4. DOI: 10.1016/j.bmcl.2016.02.063. View

14.

Mondal M, Hirsch A . Dynamic combinatorial chemistry: a tool to facilitate the identification of inhibitors for protein targets. Chem Soc Rev. 2015; 44(8):2455-88. DOI: 10.1039/c4cs00493k. View

15.

Singh N, Yeh P . Suppressive drug combinations and their potential to combat antibiotic resistance. J Antibiot (Tokyo). 2017; 70(11):1033-1042. PMC: 5659931. DOI: 10.1038/ja.2017.102. View

16.

Repetto G, Peso A, Zurita J . Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc. 2008; 3(7):1125-31. DOI: 10.1038/nprot.2008.75. View

17.

Van Voorhis W, Adams J, Adelfio R, Ahyong V, Akabas M, Alano P . Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond. PLoS Pathog. 2016; 12(7):e1005763. PMC: 4965013. DOI: 10.1371/journal.ppat.1005763. View

18.

Davis R, Sykes M, Avery V, Camp D, Quinn R . Convolutamines I and J, antitrypanosomal alkaloids from the bryozoan Amathia tortusa. Bioorg Med Chem. 2011; 19(22):6615-9. DOI: 10.1016/j.bmc.2011.06.006. View

19.

Liu X, Qian X, Xie Y, Qi Y, Peng M, Zhan B . Betaine suppressed Aβ generation by altering amyloid precursor protein processing. Neurol Sci. 2014; 35(7):1009-13. DOI: 10.1007/s10072-014-1630-y. View

20.

Tan S, Chew S, Tan S, Givskov M, Yang L . Emerging frontiers in detection and control of bacterial biofilms. Curr Opin Biotechnol. 2014; 26:1-6. DOI: 10.1016/j.copbio.2013.08.002. View